• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndrome

byIyas DaghlasandDayton McMillan
May 24, 2018
in Chronic Disease, Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Amongst adults and children with the Lennox-Gastaut (LG) syndrome, addition of cannabidiol to a conventional antiepileptic regimen reduced drop seizure frequency compared to placebo treated patients.

2. The most common adverse events amongst patients treated with cannabidiol were diarrhea, somnolence, and decreased appetite. These effects were dose-dependent.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The LG syndrome is a developmental form of epilepsy. The syndrome is partly characterized by drop seizures, which can result in serious injury and significantly reduce patient quality of life. Cannabidiol has been shown to reduce the frequency of seizures in other settings, but its role in the treatment of LG syndrome remains unclear. Investigators sought to determine whether treatment with cannabidiol would significantly reduce rates of the primary outcome, the in frequency of drop seizures compared to baseline. In this multicenter randomized controlled trial, cannabidiol was found to significantly reduce the frequency of the primary outcome at fourteen weeks.

Strengths of this study include its randomized, multicenter study design, and recruitment of more patients than originally planned. Weaknesses include the use of percent change scores as the primary outcome and short follow-up time.

Click to read the study, published in NEJM

Relevant Reading: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

RELATED REPORTS

Dietary interventions effective in treating pediatric drug-resistant epilepsy

Oxygenation strategies inconsequential in comatose survivors of cardiac arrest

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

In-Depth [randomized controlled trial]: This was a phase III, multicenter, randomized controlled trial. The study population comprised patients aged 2-55 years with the LG syndrome, electroencephalogram findings characteristic of the disease, a history of drop seizures, and treatment with one to four antiepileptics (n=225). Nonpharmacological interventions were permitted so long as they were stable before and during the trial. Key exclusion criteria included use of cannabis in the previous three months or a history of substance or alcohol use. The interventions in the trial included either 20mg/kg/day (n=76) or 10mg/kg/day (n=73) of cannabidol, and placebo (n=76). The primary outcome consisted of the percent change in drop seizure frequency from baseline after a fourteen-week treatment period. Key secondary outcomes included comparison of the percentage of patients whose seizure frequency was cut in half, change in frequency of all seizure types, and a scale reflecting the caregiver’s impression of change.

Cannabidiol at both 20mg/kg/day and 10mg/kg/day dosing was superior to placebo (Difference in percent change20 vs. placebo=21.6%; 95% confidence interval [CI], 6.7 to 34.8; P=0.005; Difference in percent change10 vs. placebo=19.2%, 95% CI, 7.7 to 31.2, p = 0.002). All the aforementioned secondary outcomes were significantly improved in both treatment arms relative to placebo. Eighty-nine percent of adverse events were judged to be mild-moderate in severity, and were most commonly somnolence, decreased appetite, and diarrhea. The most common adverse event precipitating withdrawal from the trial was elevation in aminotransferases.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: epilepsylennox gastautseizures
Previous Post

Budesonide-formoterol as needed superior to terbutaline in mild asthma: The SYGMA trial

Next Post

2 Minute Medicine Rewind May 28, 2018

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Chronic Disease

Dietary interventions effective in treating pediatric drug-resistant epilepsy

February 20, 2023
Wound surgical device found ineffective at infection control: ROSSINI Trial
Cardiology

Oxygenation strategies inconsequential in comatose survivors of cardiac arrest

October 26, 2022
Patient Basics: Seizure
Chronic Disease

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

October 24, 2022
Paternal factors associated with short interpregnancy interval
Neurology

Prenatal exposure to high-dose folic acid associated with increased cancer risk in children of mothers with epilepsy

October 1, 2022
Next Post
Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind May 28, 2018

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Physicians report feeling moral distress over hospital policies that force inadequate care based on immigration status

Safety confirmation of propranolol use in treatment of infantile hemangiomas

Safety confirmation of propranolol use in treatment of infantile hemangiomas

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options